HIV Pre-exposure Prophylaxis: Clinical Implications and Real-World Effectiveness
- *Corresponding Author:
- Jason F. Okulicz
Infectious Disease Service
San Antonio Military Medical Center
San Antonio, Brooke Army Medical Center
3551 Roger Brooke Drive, Fort Sam Houston
TX 78234-6200, USA
Tel: (210) 916- 4355
Fax: (210) 916-5900
E-mail: [email protected]
Received Date: November 29, 2012; Accepted Date: November 30, 2012; Published Date: December 03, 2012
Citation: Li J, Dufrene SL, Okulicz JF (2012) HIV Pre-exposure Prophylaxis: Clinical Implications and Real-World Effectiveness. J AIDS Clinic Res 3:e110. doi:10.4172/2155-6113.1000e110
Copyright: © 2012 Li J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The use of tenofovir-emtricitabine as pre-exposure prophylaxis (PrEP) represents the latest strategy to prevent the acquisition of HIV by uninfected individuals. Despite clinical trials exhibiting significant risk reductions with PrEP, several limitations may hinder its real-world effectiveness. PrEP functions as one component of a comprehensive prevention program, which should also include intensive counseling on the importance of adherence, reduction of high-risk behaviors, and continued use of traditional preventative methods. Additionally, the greatest impact of PrEP, both clinically and financially, will likely arise from careful application in select high-risk populations. If properly implemented, PrEP has the potential to significantly reduce the incidence of new HIV infections.